ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1456

A Tolerogenic Peptide Down-Regulates the Expression of Interferon-a in Murine and Human Systemic Lupus Erythematosus

Zev M. Sthoeger1, Heidy Zinger2, Amir Sharabi2, Ilan Asher1 and Edna Mozes2, 1Department of Medicine, Kaplan Hospital, Rehovot, Israel, 2The Weizmann institute of Science, Rehovot, Israel

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Interferons and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The tolerogenic peptide, designated hCDR1, was shown to ameliorate manifestations of systemic lupus erythematosus (SLE)  via down-regulation of pro-inflammatory cytokines, up-regulation of immunosuppressive cytokines and molecules  and  the induction of regulatory T cells.  Because type I interferon (IFN-a) has been implicated to play a major role in the pathogenesis of SLE, in the present studies we investigated the effects of hCDR1 on IFN-a in a murine model of SLE and in human lupus.

Methods:

(NZBxNZW)F1 female mice with established SLE manifestations were treated with hCDR1 (10 weekly subcutaneously injections) or  with the vehicle alone. The effects on anti-dsDNA antibody levels, proteinuria and kidney immunohistology were assessed. Splenocytes were obtained for gene expression studies. Peripheral blood lymphocytes (PBL) of lupus patients (10), primary anti-phospholipid syndrome (APS) patients (5) and healthy controls (5) were incubated in vitro for 48 hours with hCDR1 or medium prior to gene expression assays. Lupus patients were treated for 26 weeks with hCDR1 (5) or placebo (4) in a Phase II clinical trial by weekly subcutaneous injections. Disease activity was assessed using SLEDAI-2K and BILAG scores [1]. Blood samples were collected, before and after treatment, in PAXgene tubes and frozen until mRNA isolation. Gene expression of IFN-a was determined by real-time RT-PCR.

Results:

Treatment of (NZBxNZW)F1 SLE afflicted mice with hCDR1 down-regulated significantly IFN-a gene expression (73% inhibition compared to vehicle, p= 0.002). The latter was associated with diminished anti-dsDNA titers as well as proteinuria and glomerular immune complex deposit levels. Further, hCDR1 reduced, in vitro, the IFN-a gene expression in PBL of lupus patients (74% inhibition compared to medium, p=0.002). hCDR1 had no significant effects on the expression levels of IFN-a in PBL of primary APS patients or of healthy controls. Moreover, a significant reduction in IFN-a was determined in PBL of lupus patients that were treated with hCDR1 for 26 weeks (64.4% inhibition compared to pretreatment expression levels, p=0.015).  No inhibition of IFN-a expression was observed in PBL of placebo treated patients.  In agreement, as previously reported, treatment with hCDR1, but not with placebo, resulted in a significant decrease of disease activity as determined by the BILAG and SLEDAI-2K scores [1].

Conclusion:

Treatment with hCDR1 resulted in a significant amelioration of lupus manifestations in murine models. Studies of a limited number of lupus patients indicated beneficial effects in hCDR1 treated patients. We reported previously that hCDR1 affected various cell types and immune pathways involved in the pathogenesis of SLE. The present studies demonstrate that hCDR1 is also capable of down-regulating significantly (and specifically to lupus) IFN-a that has been recently considered as a target for SLE therapy.  Thus, hCDR1 has a potential role as a novel, disease specific treatment for human lupus.

[1] Journal of Autoimmunity, 33 (2009) 77-82.


Disclosure:

Z. M. Sthoeger,
None;

H. Zinger,
None;

A. Sharabi,
None;

I. Asher,
None;

E. Mozes,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-tolerogenic-peptide-down-regulates-the-expression-of-interferon-a-in-murine-and-human-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology